ATRenew (NYSE:RERE – Get Free Report) will be announcing its earnings results before the market opens on Wednesday, November 20th. Analysts expect the company to announce earnings of $0.05 per share for the quarter. ATRenew has set its Q3 2024 guidance at EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.
ATRenew (NYSE:RERE – Get Free Report) last posted its quarterly earnings results on Tuesday, August 20th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.01). ATRenew had a positive return on equity of 4.80% and a negative net margin of 0.99%. The company had revenue of $519.69 million during the quarter, compared to analysts’ expectations of $514.00 million. On average, analysts expect ATRenew to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
ATRenew Stock Performance
ATRenew stock opened at $2.39 on Monday. ATRenew has a twelve month low of $1.01 and a twelve month high of $3.18. The firm has a market cap of $582.85 million, a PE ratio of -26.55, a P/E/G ratio of 0.55 and a beta of -0.13. The firm’s 50 day moving average price is $2.52 and its two-hundred day moving average price is $2.47.
About ATRenew
ATRenew Inc, through its subsidiaries, operates pre-owned consumer electronics transactions and services platform in the People's Republic of China. It primarily sells mobile phones, laptops, tablets, drones, digital cameras; and vintage bags, watches, liquor, gold, and various household goods through its online platforms and offline stores, as well as provides services to third-party merchants to sell the products through its platforms.
Featured Stories
- Five stocks we like better than ATRenew
- Canadian Penny Stocks: Can They Make You Rich?
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Following Congress Stock Trades
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for ATRenew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ATRenew and related companies with MarketBeat.com's FREE daily email newsletter.